111429-90-4

Basic information

• Product Name: 4-[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)ethoxy]-3-oxobutanoic Acid Methyl Ester
• Synonyms: 4-[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)ethoxy]-3-oxobutanoic Acid Methyl Ester;methyl 4-[2-(phthalimido)-ethoxy]acetoacetate;methyl 4-[2-(phthalimido)-ethoxy]acetoacetate（WS202129）
• CAS NO: 111429-90-4
• Molecular Formula: C₁₅H₁₅NO₆
• Molecular Weight: 305.2827
• Mol File: 111429-90-4.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 470.2±30.0 °C(Predicted)
• Appearance: /
• Density: 1.329±0.06 g/cm3(Predicted)
• Solubility: DCM, Ethyl Acetate, Methanol
• PKA: 9.81±0.46(Predicted)
• CAS DataBase Reference: 4-[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)ethoxy]-3-oxobutanoic Acid Methyl Ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)ethoxy]-3-oxobutanoic Acid Methyl Ester(111429-90-4)
• EPA Substance Registry System: 4-[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)ethoxy]-3-oxobutanoic Acid Methyl Ester(111429-90-4)

Safety Data

• Hazardous Substances Data: 111429-90-4(Hazardous Substances Data)

Usage

Uses

4-[2-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)ethoxy]-3-oxobutanoic Acid Methyl Ester is an intermediate in the synthesis of Amlodipine Besilate (A633500) related compounds.

Upstream product

• 3891-07-4 N-(2-Hydroxyethyl)phthalimide 
• 32807-28-6 Methyl 4-chloroacetoacetate 

Downstream Products

• 1252017-21-2 methyl 2-[4-bromobenzylidene]-4-[2-(phthalimido)-ethoxy]acetoacetate 
• 1252017-23-4 methyl 2-[2-hydroxybenzylidene]-4-[2-(phthalimido)-ethoxy]acetoacetate 
• 1252017-22-3 methyl 2-[4-methoxybenzylidene]-4-[2-(phthalimido)-ethoxy]acetoacetate 
• 1252017-24-5 methyl 2-[3,4,5-trimethoxybenzylidene]-4-[2-(phthalimido)-ethoxy]acetoacetate 
• 110980-79-5 methyl 2-[3-nitrobenzylidene]-4-[2-(phthalimido)-ethoxy]acetoacetate 
• 1252017-19-8 methyl 2-[4-chlorobenzylidene]-4-[2-(phthalimido)-ethoxy]acetoacetate 
• 1252017-20-1 methyl 2-[4-fluorobenzylidene]-4-[2-(phthalimido)-ethoxy]acetoacetate 
• 140171-50-2 phthaloyl amlodipine 
• 140171-66-0 dimethyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate 

Relevant articles and documents

Preparation process of amlodipine intermediate

The invention relates to a method for preparing an amlodipine intermediate safely and efficiently (the formula is as shown in the description). The method particularly comprises the following steps: step 1, heating 4-chloroacetoacetic acid ethyl ester and para-toluenesulfonic acid sodium salt which serve as raw materials in a reaction solvent and performing reaction to obtain a compound 2; and step 2, adding an alkaline compound serving as a catalyst into the compound 2 and N-hydroxyethylphthalimide, adding a phase transfer catalyst simultaneously and heating to obtain a compound 1. The intermediate compound 2 adopts 4-chloroacetoacetic acid ethyl ester protected by para-toluenesulfonic acid, and p-toluenesulfonate is adopted, so the condition of an etherification step is greatly reduced,dangerous or expensive reagents are avoided and the production safety is greatly improved.

Synthesis of some novel chalcones of phthalimidoester possessing good antiinflammatory and antimicrobial activity

A new series of methyl-2-[substituted benzylidine]-4-[2-(phthalimide) ethoxy] acetoacetate, 5a-h have been synthesized from the combination of methyl-4-[2-(phthalimido) ethoxy] acetoacetate, 3 and substituted benzaldehyde 4a-h which results in both anti-inflammatory and antimicrobial active compound. These compounds have been characterized by IR, 1H NMR, mass spectral and elemental analysis. These compounds have been subjected to preliminary anti-inflammatory screening using the carrageenan induced rat pow oedema model. Compounds 5a,b,c show marked activity comparable to indomethacin. Compounds 5a,b,c,g show significant antimicrobial activity.

DIHYDROPYRIDINE COMPOUNDS HAVING SIMULTANEOUS ABILITY TO BLOCK L-TYPE CALCIUM CHANNELS AND TO INHIBIT PHOSPHODIESTERASE TYPE 3 ACTIVITY

The present invention provides compounds that possess inhibitory activity against PDE-3 and L-type calcium channels. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating cardiovascular disease, stroke, epilepsy, ophthalmic disorder or migraine.